





BioSyent Inc. Q3 2013 Results

Today's presentation by:
René Goehrum
Chairman and CEO

November 21, 2013

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.


Sales by Quarter and Nine months ended September



- **FeraMAX® Brand**
 - Strong base business growth
 - FeraMAX® Powder launch
- **Cathejell™ market traction – units were up 94% vs. Q2 2013**
- **The Legacy business delivered growth:**
Sales increased in both U.S. and Canada
Q3 Units:


U.S.	+ 33%
Canada	+ 8%


Sales for Nine Months Ended September




Pharmaceutical Sales By Quarter

16 Consecutive Quarters of Growth





Net Income Before & After Tax



Balance Sheet Snapshot

AS AT

December 31 December 31 September 30
2011 2012 2013

ASSETS

Trade & Other Receivables	\$ 335,186	\$ 589,697	\$ 1,202,061
Inventory	121,283	345,630	637,069
Prepaid expenses & deposits	35,921	71,257	181,155
Cash & Cash Equivalents	1,058,046	2,316,055	3,180,832

CURRENT ASSETS

\$ 1,550,436 \$ 3,322,639 \$ 5,201,117

Equipment	30,109	97,932	147,985
Intangible Assets	4,394	0	36,997
Deferred Tax	0	232,199	190,461

TOTAL ASSETS

\$ 1,584,939 \$ 3,652,770 \$ 5,576,560

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES \$ 422,371 \$ 813,361 \$ 1,294,668

Long & Short Term Debt \$ 0 0 0

Total Equity \$ 1,162,568 \$ 2,839,409 \$ 4,281,892

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

\$ 1,584,939 \$ 3,652,770 \$ 5,576,560

OPEX	Expense by Quarter			Expense in the first nine months		
	Q3 2012	Q3 2013	% Change	Sept 2012	Sept 2013	% Change
Selling & Marketing	399,174	623,286	56%	856,535	1,416,954	65%
General & Administration	398,627	388,466	-3%	1,005,609	1,202,701	20%
All Other Expenses Taken Together	458	7,676	N.A.	7,436	7,568	N.A.
Operating Expenses	798,259	1,019,428	28%	1,869,580	2,627,223	41%

Q3 Revenue Increase
vs. 2012

48%

Nine Months Revenue Increase
vs. 2012


53%

Earnings Per Share YTD September 30

	9 Months			3 Months
	2011	2012	2013	Q3 2013
Numerator				
Net income attributable to common shareholders	\$ 349,452	\$ 1,037,885	\$ 1,372,484	\$ 609,749
Denominator				
Basic				
Weighted average number of shares outstanding	12,521,195	12,721,195	13,437,976	13,437,976
Effect of Dilutive Securities adjusted for exercised options	401,087	1,457,187	1,114,742	820,505
Diluted				
Weighted average number of shares outstanding	12,922,282	14,178,382	14,552,718	14,258,481
Basic earnings per share	\$ 0.03	\$ 0.08	\$ 0.10 *	\$ 0.05 *
Diluted earnings per share	\$ 0.03	\$ 0.07	\$ 0.09 *	\$ 0.04 *

*** No Tax Expense for the first nine months of 2011 & 2012
Tax Expense first nine months 2013 : \$0.03 per share**

- **Announced the in-licensing of a new Women's Health product**
 - New European partner (3rd partner from Europe)
 - Already Health Canada approved
 - Complimentary to FeraMAX® 150 promotion targets
 - Launch planning in full swing – Q2 target timing
- **Cathejell™ set a new monthly record (October) since launch sell-in during June and August 2012**
- **October total Pharma shipments set an all-time record**
 - \$ value up 25% vs. the previous best month



3 products currently planned for 2014 launch
 - 2 dependent on Health Canada approval



Thank you.

www.biosyent.com

www.sedar.com

www.tmxmoney.com

www.feramax.com

www.cathejell.ca